Compare RAVE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | VERU |
|---|---|---|
| Founded | 1958 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.5M | 39.8M |
| IPO Year | N/A | 1990 |
| Metric | RAVE | VERU |
|---|---|---|
| Price | $3.05 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 41.4K | ★ 170.9K |
| Earning Date | 02-05-2026 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.08 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $12,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.12 | ★ N/A |
| Revenue Growth | ★ 0.73 | N/A |
| 52 Week Low | $2.01 | $2.11 |
| 52 Week High | $3.75 | $14.20 |
| Indicator | RAVE | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 39.32 |
| Support Level | $2.74 | $2.17 |
| Resistance Level | $2.97 | $2.49 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 57.71 | 26.42 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.